Documents

4–7 BLA submitted; cash runway extends into Q3 2027 as launch preparations advance.

Patch-based peanut allergy therapy offers safe, effective, and convenient long-term desensitization.

BLA submission for VIASKIN Peanut Patch set for Q3 2026, with funding secured into Q3 2027.

FDA feedback streamlines BLA submission for VIASKIN Peanut patch, with Q3 filing on track.

Skin-based immunotherapy for peanut allergy nears FDA filing, with pipeline and market expansion ahead.

VIASKIN Peanut patch shows robust efficacy and safety, targeting a major pediatric allergy market.

Cash reserves up to $229M; net loss widens as launch and regulatory prep for VIASKIN advance.

Peanut allergy patch therapy nears launch with strong data, targeting young children and future pipeline growth.

Viaskin Peanut advances toward 2026 BLAs and 2027 launch, backed by robust clinical data.

Patch-based immunotherapy for pediatric peanut allergy advances toward US and EU approval.

Advanced VIASKIN Peanut Patch programs and secured funding support cash runway into Q2 2027.

VITESSE phase III trial met its primary endpoint, supporting BLA submission and strong market potential.

Highly powered pediatric peanut allergy patch trial nears data readout, supporting 2026 launch.

Cash runway extends into Q3 2026, but going concern risks persist amid ongoing losses.

Net loss widened to $69.0M in H1 2025, but cash reserves rose to $103.2M after new financing.